REIN THERAPEUTICS INC (RNTX) Fundamental Analysis & Valuation

NASDAQ:RNTX • US00887A2042

Current stock price

1.45 USD
-0.04 (-2.68%)
At close:
1.3 USD
-0.15 (-10.34%)
Pre-Market:

This RNTX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. RNTX Profitability Analysis

1.1 Basic Checks

  • RNTX had negative earnings in the past year.
  • RNTX had a negative operating cash flow in the past year.
  • RNTX had negative earnings in each of the past 5 years.
  • RNTX had a negative operating cash flow in each of the past 5 years.
RNTX Yearly Net Income VS EBIT VS OCF VS FCFRNTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -20M -40M -60M

1.2 Ratios

  • RNTX has a Return On Assets of -206.44%. This is amonst the worse of the industry: RNTX underperforms 89.51% of its industry peers.
  • RNTX has a Return On Equity of -294.78%. This is in the lower half of the industry: RNTX underperforms 74.95% of its industry peers.
Industry RankSector Rank
ROA -206.44%
ROE -294.78%
ROIC N/A
ROA(3y)-107.46%
ROA(5y)-100.1%
ROE(3y)-142.13%
ROE(5y)-126.55%
ROIC(3y)N/A
ROIC(5y)N/A
RNTX Yearly ROA, ROE, ROICRNTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50 -100 -150 -200 -250

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for RNTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RNTX Yearly Profit, Operating, Gross MarginsRNTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. RNTX Health Analysis

2.1 Basic Checks

  • RNTX has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, RNTX has more shares outstanding
  • RNTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
RNTX Yearly Shares OutstandingRNTX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M 25M
RNTX Yearly Total Debt VS Total AssetsRNTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

2.2 Solvency

  • RNTX has an Altman-Z score of -22.97. This is a bad value and indicates that RNTX is not financially healthy and even has some risk of bankruptcy.
  • RNTX has a worse Altman-Z score (-22.97) than 86.21% of its industry peers.
  • RNTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -22.97
ROIC/WACCN/A
WACCN/A
RNTX Yearly LT Debt VS Equity VS FCFRNTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M 60M 80M

2.3 Liquidity

  • RNTX has a Current Ratio of 0.70. This is a bad value and indicates that RNTX is not financially healthy enough and could expect problems in meeting its short term obligations.
  • RNTX has a worse Current ratio (0.70) than 90.68% of its industry peers.
  • A Quick Ratio of 0.70 indicates that RNTX may have some problems paying its short term obligations.
  • RNTX has a worse Quick ratio (0.70) than 90.49% of its industry peers.
Industry RankSector Rank
Current Ratio 0.7
Quick Ratio 0.7
RNTX Yearly Current Assets VS Current LiabilitesRNTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. RNTX Growth Analysis

3.1 Past

  • RNTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 51.53%, which is quite impressive.
EPS 1Y (TTM)51.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50.35%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, RNTX will show a small growth in Earnings Per Share. The EPS will grow by 5.89% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y54.91%
EPS Next 2Y12.23%
EPS Next 3Y5.89%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
RNTX Yearly Revenue VS EstimatesRNTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2030 2031 2032 2033 100M 200M 300M
RNTX Yearly EPS VS EstimatesRNTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 -10 -20 -30 -40

More info and screens

Find the best growth stocksShow best growing peers

0

4. RNTX Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for RNTX. In the last year negative earnings were reported.
  • Also next year RNTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RNTX Price Earnings VS Forward Price EarningsRNTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RNTX Per share dataRNTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1 -1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y12.23%
EPS Next 3Y5.89%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. RNTX Dividend Analysis

5.1 Amount

  • RNTX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

RNTX Fundamentals: All Metrics, Ratios and Statistics

REIN THERAPEUTICS INC

NASDAQ:RNTX (4/28/2026, 8:00:02 PM)

Premarket: 1.3 -0.15 (-10.34%)

1.45

-0.04 (-2.68%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Industry Strength55.9
Industry Growth13.66
Earnings (Last)03-26
Earnings (Next)05-13
Inst Owners38.6%
Inst Owner Change0.18%
Ins Owners0.07%
Ins Owner ChangeN/A
Market Cap40.66M
Revenue(TTM)N/A
Net Income(TTM)-49.87M
Analysts80
Price Target10.2 (603.45%)
Short Float %0.84%
Short Ratio2.1
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-191.93%
Min EPS beat(2)-398.08%
Max EPS beat(2)14.22%
EPS beat(4)1
Avg EPS beat(4)-102.17%
Min EPS beat(4)-398.08%
Max EPS beat(4)14.22%
EPS beat(8)2
Avg EPS beat(8)-290.47%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)25%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.4
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.83
EYN/A
EPS(NY)-0.83
Fwd EYN/A
FCF(TTM)-0.69
FCFYN/A
OCF(TTM)-0.69
OCFYN/A
SpS0
BVpS0.6
TBVpS-0.1
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -206.44%
ROE -294.78%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-107.46%
ROA(5y)-100.1%
ROE(3y)-142.13%
ROE(5y)-126.55%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.7
Quick Ratio 0.7
Altman-Z -22.97
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)51.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50.35%
EPS Next Y54.91%
EPS Next 2Y12.23%
EPS Next 3Y5.89%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y21.99%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y13.14%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y13.14%
OCF growth 3YN/A
OCF growth 5YN/A

REIN THERAPEUTICS INC / RNTX Fundamental Analysis FAQ

What is the fundamental rating for RNTX stock?

ChartMill assigns a fundamental rating of 1 / 10 to RNTX.


What is the valuation status of REIN THERAPEUTICS INC (RNTX) stock?

ChartMill assigns a valuation rating of 0 / 10 to REIN THERAPEUTICS INC (RNTX). This can be considered as Overvalued.


Can you provide the profitability details for REIN THERAPEUTICS INC?

REIN THERAPEUTICS INC (RNTX) has a profitability rating of 0 / 10.